Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Lenvatinib or Regorafenib in Unresectable or Metastatic Hepatocellular Carcinoma After Progression on First-line Immunotherapy-based Combination Therapy
KCT0011148Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, regorafenib in hepatocellular carcinoma (HCC), sponsored by Boryung. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
lenvatinibregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0011148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011148.